Skip to main content

Detail

Yen Y. Tan
Yen Y. Tan, PhDCancer Epidemiologist

Department of Obstetrics and Gynecology (Division of General Gynecology and Gynecologic Oncology)
Position: Lecturer

ORCID: 0000-0003-1063-5352
yen.tan@meduniwien.ac.at

Further Information

Keywords

DNA Mismatch Repair; Epidemiology; Genes, BRCA1; Genes, BRCA2; Hereditary Breast and Ovarian Cancer Syndrome; Lynch Syndrome II

Research group(s)

Research interests

My research interests cover all aspects of the epidemiology of hereditary breast, ovarian and endometrial cancer, with a focus in prediction of breast cancer risk and outcomes for the high-risk population.

My current focus includes male breast cancer, treatment responses and health outcomes of BRCA-associated metastatic breast cancer, and patient-reported outcomes in hereditary cancer patients. I am also interested in the etiology and prevention of prostate cancer, particularly BRCA-associated prostate cancer.

Grants

  • Austrian BRCA‐associated metastatic breast cancer registry (2019)
    Source of Funding: Pfizer, Research Grant
    Principal Investigator
  • BRCA-P - Prospectively randomized place-controlled phase 3 study to determine the effect of denosumab on breast cancer prevention in BRCA1 mutation carriers (2019)
    Source of Funding: U.S. Department of Defense, Breast Cancer Research Program Breakthrough Award - Funding Level 4
    Coordinator of the collaborative project

Selected publications

  1. Qian, F. et al., 2019. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 121(2), pp.180–192. Available at: http://dx.doi.org/10.1038/s41416-019-0492-8.
  2. Kuchenbaecker, K.B. et al., 2017. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), p.2402. Available at: http://dx.doi.org/10.1001/jama.2017.7112.
  3. Johnatty, S.E. et al., 2017. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic Oncology, 147(2), pp.381–387. Available at: http://dx.doi.org/10.1016/j.ygyno.2017.08.011.
  4. Buchanan, D.D. et al., 2014. Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. Journal of Clinical Oncology, 32(2), pp.90–100. Available at: http://dx.doi.org/10.1200/JCO.2013.51.2129.
  5. Tan, Y.Y. et al., 2013. Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 132(12), pp.2876–2883. Available at: http://dx.doi.org/10.1002/ijc.27978.